Researchers at the University of California, San Diego School of Medicine, in partnership with ViaCyte, Inc., a San Diego-based biotechnology firm specializing in regenerative medicine, have launched the first-ever human Phase I/II clinical trial of a stem cell-derived therapy for patients with Type 1 diabetes.
Meanwhile, health care is increasingly moving toward the use of biometric devices – gadgets embedded with wireless sensors – to unobtrusively monitor patients’ health data in real time, from blood pressure and insulin levels to number of steps walked per day.
Racetrack Playa is home to an enduring Death Valley mystery. Littered across the surface of this dry lake, also called a “playa,” are hundreds of rocks – some weighing as much as 320 kilograms (700 pounds) – that seem to have been dragged across the ground, leaving synchronized trails that can stretch for hundreds of meters.
The San Diego Supercomputer Center (SDSC) at the University of California, San Diego, is working with semiconductor chipmaker Intel Corporation to further optimize research software to improve the parallelism, efficiency, and scalability of widely used molecular and neurological simulation technologies.
The effort to develop therapeutics and a vaccine against the deadly Ebola virus disease (EVD) requires a complex understanding of the microorganism and its relationship within the host, especially the immune response. Adding to the challenge, EVD can be caused by any one of five known species within the genus Ebolavirus (EBOV), in the Filovirus family.
The University of California, San Diego is ranked the 8th best public university in the nation by U.S. News & World Report. The publication’s 2015 Best Colleges guidebook, released today, ranks UC San Diego 37th best university in the U.S. among more than 200 public, private and for-profit institutions.
Keep up with all the latest from UC San Diego. Subscribe to the newsletter today.
